e.valuation, translational: add innovation
Optimal assessment of biomarker and target candidates together with potency of compounds from initial screening results is critical for concluding on promising hits to further explore - without missing alternatives and novels. Here heterogeneous research data need to be set into context, and relevance of novel findings need to be evaluated in the light of the clinical phenotype and effective clinical use in focus.
e.valuation application scenarios in translational asset discovery/verification stage include:
- evaluate plausibility of biomarker, target or drug hits from discovery
- check on alternative biomarkers, targets or compound classes
- decrease cycle time
e.valuation provides dedicated workflows tailored at interpretation of results from heterogeneous discovery studies. Be it from functional assays, high throughput screening or Omics profiling, our platform early on provides an integrative perspective: big data-driven asset translation.